after MERS the South Koreans also created a regulatory model that had their CDC and FDA working together to advance new tests in the setting of public health crises. Under the approach, the South Korean CDC would do its own clinical evaluation of new diagnostic kits to validate their accuracy using patient samples that the agency would have access to. It would then send the data it generated to the South Korean FDA to do an independent review and issue the equivalent of an emergency-use authorization. The key advance was the commitment by the South Korean CDC to use patient samples to do the
...more
